Management of immune-mediated uveitis

Justine R. Smith, James (Jim) Rosenbaum

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Immune-mediated uveitis is a collective term referring to a group of potentially blinding intraocular inflammations which may coexist with systemic inflammatory diseases. T lymphocytes appear to play an important pathogenic role in uveitis, and these cells are therefore the logical target of drug therapy. Corticosteroids act nonspecifically, but are highly effective in controlling the inflammation rapidly. They are administered locally when disease is confined to the anterior portion of the eye. However, posterior eye involvement often requires systemic corticosteroid therapy, carrying a high risk of serious adverse effects when used for extended periods. In this situation, steroid-sparing agents are used. Few relevant randomised, controlled clinical trials have been performed, and the choice of systemic immunosuppressive regimen is usually guided by individual patient characteristics, cost, drug availability and physician preference. Patients should actively participate in therapeutic decision-making. Our first choice for steroid-sparing medication is often methotrexate, an antimetabolite which carries a low risk of adverse reactions when appropriately prescribed and monitored, is relatively inexpensive, and has once-weekly ease of use. For more severe uveitis, we may combine the immunomodulating agent cyclosporin with methotrexate and a corticosteroidl Azathioprine and cyclophosphamide are other treatment options. Steroid-sparing drugs also have significant potential for causing adverse effects, albeit less frequently than corticosteroids. Future therapies aim to reduce this problem by increasing the specificity of the therapeutic action.

Original languageEnglish (US)
Pages (from-to)9-20
Number of pages12
JournalBioDrugs
Volume13
Issue number1
StatePublished - 2000

Fingerprint

Uveitis
Adrenal Cortex Hormones
Steroids
Methotrexate
Inflammation
Therapeutics
Antimetabolites
Drug Costs
Azathioprine
Immunosuppressive Agents
Cyclophosphamide
Cyclosporine
Decision Making
Randomized Controlled Trials
Physicians
T-Lymphocytes
Drug Therapy
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Immunology and Allergy
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Management of immune-mediated uveitis. / Smith, Justine R.; Rosenbaum, James (Jim).

In: BioDrugs, Vol. 13, No. 1, 2000, p. 9-20.

Research output: Contribution to journalArticle

Smith, JR & Rosenbaum, JJ 2000, 'Management of immune-mediated uveitis', BioDrugs, vol. 13, no. 1, pp. 9-20.
Smith, Justine R. ; Rosenbaum, James (Jim). / Management of immune-mediated uveitis. In: BioDrugs. 2000 ; Vol. 13, No. 1. pp. 9-20.
@article{cb6defece66b47a98e175da272fa26fd,
title = "Management of immune-mediated uveitis",
abstract = "Immune-mediated uveitis is a collective term referring to a group of potentially blinding intraocular inflammations which may coexist with systemic inflammatory diseases. T lymphocytes appear to play an important pathogenic role in uveitis, and these cells are therefore the logical target of drug therapy. Corticosteroids act nonspecifically, but are highly effective in controlling the inflammation rapidly. They are administered locally when disease is confined to the anterior portion of the eye. However, posterior eye involvement often requires systemic corticosteroid therapy, carrying a high risk of serious adverse effects when used for extended periods. In this situation, steroid-sparing agents are used. Few relevant randomised, controlled clinical trials have been performed, and the choice of systemic immunosuppressive regimen is usually guided by individual patient characteristics, cost, drug availability and physician preference. Patients should actively participate in therapeutic decision-making. Our first choice for steroid-sparing medication is often methotrexate, an antimetabolite which carries a low risk of adverse reactions when appropriately prescribed and monitored, is relatively inexpensive, and has once-weekly ease of use. For more severe uveitis, we may combine the immunomodulating agent cyclosporin with methotrexate and a corticosteroidl Azathioprine and cyclophosphamide are other treatment options. Steroid-sparing drugs also have significant potential for causing adverse effects, albeit less frequently than corticosteroids. Future therapies aim to reduce this problem by increasing the specificity of the therapeutic action.",
author = "Smith, {Justine R.} and Rosenbaum, {James (Jim)}",
year = "2000",
language = "English (US)",
volume = "13",
pages = "9--20",
journal = "BioDrugs",
issn = "1173-8804",
publisher = "Adis International Ltd",
number = "1",

}

TY - JOUR

T1 - Management of immune-mediated uveitis

AU - Smith, Justine R.

AU - Rosenbaum, James (Jim)

PY - 2000

Y1 - 2000

N2 - Immune-mediated uveitis is a collective term referring to a group of potentially blinding intraocular inflammations which may coexist with systemic inflammatory diseases. T lymphocytes appear to play an important pathogenic role in uveitis, and these cells are therefore the logical target of drug therapy. Corticosteroids act nonspecifically, but are highly effective in controlling the inflammation rapidly. They are administered locally when disease is confined to the anterior portion of the eye. However, posterior eye involvement often requires systemic corticosteroid therapy, carrying a high risk of serious adverse effects when used for extended periods. In this situation, steroid-sparing agents are used. Few relevant randomised, controlled clinical trials have been performed, and the choice of systemic immunosuppressive regimen is usually guided by individual patient characteristics, cost, drug availability and physician preference. Patients should actively participate in therapeutic decision-making. Our first choice for steroid-sparing medication is often methotrexate, an antimetabolite which carries a low risk of adverse reactions when appropriately prescribed and monitored, is relatively inexpensive, and has once-weekly ease of use. For more severe uveitis, we may combine the immunomodulating agent cyclosporin with methotrexate and a corticosteroidl Azathioprine and cyclophosphamide are other treatment options. Steroid-sparing drugs also have significant potential for causing adverse effects, albeit less frequently than corticosteroids. Future therapies aim to reduce this problem by increasing the specificity of the therapeutic action.

AB - Immune-mediated uveitis is a collective term referring to a group of potentially blinding intraocular inflammations which may coexist with systemic inflammatory diseases. T lymphocytes appear to play an important pathogenic role in uveitis, and these cells are therefore the logical target of drug therapy. Corticosteroids act nonspecifically, but are highly effective in controlling the inflammation rapidly. They are administered locally when disease is confined to the anterior portion of the eye. However, posterior eye involvement often requires systemic corticosteroid therapy, carrying a high risk of serious adverse effects when used for extended periods. In this situation, steroid-sparing agents are used. Few relevant randomised, controlled clinical trials have been performed, and the choice of systemic immunosuppressive regimen is usually guided by individual patient characteristics, cost, drug availability and physician preference. Patients should actively participate in therapeutic decision-making. Our first choice for steroid-sparing medication is often methotrexate, an antimetabolite which carries a low risk of adverse reactions when appropriately prescribed and monitored, is relatively inexpensive, and has once-weekly ease of use. For more severe uveitis, we may combine the immunomodulating agent cyclosporin with methotrexate and a corticosteroidl Azathioprine and cyclophosphamide are other treatment options. Steroid-sparing drugs also have significant potential for causing adverse effects, albeit less frequently than corticosteroids. Future therapies aim to reduce this problem by increasing the specificity of the therapeutic action.

UR - http://www.scopus.com/inward/record.url?scp=0033963391&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033963391&partnerID=8YFLogxK

M3 - Article

C2 - 18034509

AN - SCOPUS:0033963391

VL - 13

SP - 9

EP - 20

JO - BioDrugs

JF - BioDrugs

SN - 1173-8804

IS - 1

ER -